Leerink Partners Reaffirms Their Hold Rating on Invitae (NVTA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Invitae (NVTA), Roivant Sciences (ROIV) and Exact Sciences (EXAS)
Invitae Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ScPharmaceuticals (SCPH) and Invitae (NVTA)
Piper Sandler Reaffirms Their Sell Rating on Invitae (NVTA)
Analysts Conflicted on These Healthcare Names: Sana Biotechnology (SANA), 23andMe Holding (ME) and Invitae (NVTA)
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $0.5
Invitae Analyst Ratings
Invitae Analyst Ratings
Invitae Analyst Ratings
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $1
Invitae Analyst Ratings
Invitae Analyst Ratings
SVB Securities Sticks to Their Hold Rating for Invitae (NVTA)
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $1.5
Piper Sandler Sticks to Its Sell Rating for Invitae (NVTA)
Piper Sandler Adjusts Invitae's Price Target to $1.75 From $2.25, Keeps Underweight Rating
Piper Sandler Maintains Underweight on Invitae, Lowers Price Target to $1.75
SVB Securities Sticks to Its Hold Rating for Invitae (NVTA)
Invitae (NVTA) Receives a Hold From Raymond James